When managing idiopathic pulmonary fibrosis (IPF), there are impactful nonpharmacologic interventions and referrals that can improve patient outcomes. Read an expert’s commentary on strategies to improve quality of life and outcomes in patients with IPF.
In Partnership With the Association of Pulmonary Advanced Practice Providers
NPs and PAs
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech, a member of the Roche Group.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Kershaw: consulting fees: Boehringer Ingelheim
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 102621BI-CT